EX-99 3 y83035a1exv99.txt CERTAIN SUPPLEMENTAL INFO TO SUPPLEMENTAL INFO Exhibit 99 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2002 OTHER (INCOME)/EXPENSE, NET
4Q `02 4Q `01 YTD 2002 YTD 2001 ------ ------ -------- -------- INTEREST INCOME $ (108.1) $ (109.8) $ (419.3) $ (490.1) INTEREST EXPENSE 98.1 109.5 390.8 464.7 EXCHANGE (GAINS)/LOSSES (18.7) 15.1 (7.8) (3.5) MINORITY INTERESTS 44.5 72.3 214.2 290.6 AMORTIZATION OF GOODWILL AND INTANGIBLES 51.3 85.3 204.9 330.1 Other, net 25.1 (58.9) (79.0) (250.1) -------- -------- --------- -------- TOTAL $ 92.2 $ 113.5 $ 303.8 $ 341.7
JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis, rounded to the nearest $5 million.
MERIAL 4Q `02 4Q `01 YTD 2002 YTD 2001 ------ --------- --------- ---------- -------- IVOMEC, HEARTGARD, other avermectins $ 115 $ 130 $ 465 $ 495 FRONTLINE 75 70 485 410 Biologicals 100 100 375 355 Other Animal Health 50 45 180 190 Poultry Genetics 55 55 220 210 --------- --------- ---------- -------- TOTAL MERIAL SALES $ 395 $ 400 $ 1,725 $ 1,660 Aventis Pasteur-MSD 4Q `02 4Q `01 YTD 2002 YTD 2001 ------------------- --------- --------- ---------- -------- HEPATITIS VACCINES $ 20 $ 20 $ 70 $ 90 VIRAL VACCINES 10 5 35 40 Other Vaccines 115 105 440 370 --------- --------- ---------- -------- TOTAL AP-MSD SALES $ 145 $ 130 $ 545 $ 500
Merck / Schering-Plough Collaboration 4Q `02 4Q `01 YTD 2002 YTD 2001 ------------------------------------- ------ ------ -------- -------- Zetia (Worldwide) $ 25 N/M $ 25 N/M TOTAL $ 25 N/M $ 25 N/M
TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS) 2002
MAIL RETAIL TOTAL ---- ------ ----- FIRST QUARTER 20 121 141 SECOND QUARTER 21 119 140 THIRD QUARTER 20 110 130 FOURTH QUARTER 21 117 138 ---- ------ ----- YEAR TO DATE 82 467 548
2001
MAIL RETAIL TOTAL FIRST QUARTER 18 120 138 SECOND QUARTER 19 115 134 THIRD QUARTER 18 110 128 FOURTH QUARTER 20 117 137 ---- ------ ----- YEAR TO DATE 75 462 537
Exhibit 99
MERCK & CO., INC. NET PRODUCT SALES DETAIL -------------------------------------------------------------------- FULL YEAR 2002 OVER 2001 -------------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ----- ------ ----- ------ ------- ------- VIOXX 8% $2,530 1% $1,705 24% $ 825 ARCOXIA N/M 30 N/M -- N/M 30 VASOTEC/VASERETIC -24% 790 -100% -- -14% 790 PRINIVIL/PRINZIDE -32% 480 -33% 410 -26% 70 COZAAR/HYZAAR 21% 2,190 34% 935 13% 1,255 MEVACOR -60% 110 -76% 45 -24% 65 ZOCOR 6% 5,580 1% 3,325 14% 2,255 AGGRASTAT 0% 115 -21% 55 33% 60 SINGULAIR 19% 1,505 14% 1,090 32% 415 MAXALT 26% 295 26% 220 25% 75 PROPECIA 2% 215 -5% 100 10% 115 PROSCAR 1% 550 -2% 270 4% 280 PRIMAXIN 0% 585 12% 185 -5% 400 INVANZ N/M 15 N/M 10 N/M 5 CANCIDAS 163% 105 100% 60 N/M 45 PEPCID -80% 55 -89% 25 -50% 30 FOSAMAX 38% 2,250 34% 1,530 48% 720 CRIXIVAN/STOCRIN -25% 290 -28% 105 -23% 185 TIMOPTIC/TIMOPTIC XE -18% 165 -38% 25 -13% 140 TRUSOPT/COSOPT 5% 425 0% 185 9% 240 HEPATITIS VACCINES -12% 225 -11% 195 -14% 30 VIRAL VACCINES 11% 555 15% 530 -38% 25 OTHER VACCINES N/M 245 N/M 205 N/M 40
NOTE: Product sales rounded to the nearest $5 million. N/M - Not Meaningful